✨ Medicines Distribution Consent
13 JUNE
NEW ZEALAND GAZETTE
1613
Product:
Seretide Accuhaler
Active Ingredients:
Fluticasone propionate 250µg
Salmeterol xinafoate 72.5µg equivalent to 50µg of salmeterol base
Dosage Form:
Powder for inhalation
New Zealand Sponsor:
Glaxo Wellcome New Zealand Limited
Manufacturers:
Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom
Glaxo Wellcome Production, Evreux, France
Product:
Seretide Accuhaler
Active Ingredients:
Fluticasone propionate 500µg
Salmeterol xinafoate 72.5µg equivalent to 50µg of salmeterol base
Dosage Form:
Powder for inhalation
New Zealand Sponsor:
Glaxo Wellcome New Zealand Limited
Manufacturer:
Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom
Product:
Seretide
Active Ingredients:
Fluticasone propionate 20mg equivalent to 125µg/dos
Salmeterol xinafoate 5.8mg equivalent to 25µg/dose salmeterol
Dosage Form:
Aerosol inhaler, metered dose
New Zealand Sponsor:
Glaxo Wellcome New Zealand Limited
Manufacturers:
Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Glaxo Wellcome Production, Evreux, France
Product:
Seretide
Active Ingredients:
Fluticasone propionate 40mg equivalent to 250µg/dos
Salmeterol xinafoate 5.8mg equivalent to 25µg/dose salmeterol
Dosage Form:
Aerosol inhaler, metered dose
New Zealand Sponsor:
Glaxo Wellcome New Zealand Limited
Manufacturers:
Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Glaxo Wellcome Production, Evreux, France
Product:
Seretide
Active Ingredients:
Fluticasone propionate 8mg equivalent to 50µg/dos
Salmeterol xinafoate 5.8mg equivalent to 25µg/dose salmeterol
Dosage Form:
Aerosol inhaler, metered dose
New Zealand Sponsor:
Glaxo Wellcome New Zealand Limited
Manufacturers:
Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Glaxo Wellcome Production, Evreux, France
Dated this 5th day of June 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go3811
Consent to the Distribution of Changed Medicines
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:
Schedule
Product:
Zeffix
Active Ingredient:
Lamivudine 5mg/mL
Dosage Form:
Oral solution
New Zealand Sponsor:
Glaxo Wellcome New Zealand Limited
Manufacturer:
Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Note: This product has consent that expires on 17 September 2004.
Product:
Zeffix
Active Ingredient:
Lamivudine 100mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Glaxo Wellcome New Zealand Limited
Manufacturer:
Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom
Note: This product has consent that expires on 17 September 2004.
Dated this 5th day of June 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go3813
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2002, No 62
Gazette.govt.nz —
NZ Gazette 2002, No 62
✨ LLM interpretation of page content
🏥
Consent to the Distribution of Changed Medicines
(continued from previous page)
🏥 Health & Social Welfare5 June 2002
Medicines Act 1981, Changed Medicines, Distribution Consent, Seretide, Zeffix
- G. R. Boyd, Chief Advisor, Safety and Regulation